Forus raises $160M at $1B valuation to fix America's prescription fill rate problem
What's the deal? Forus, a New York-based healthcare AI startup formerly known as Tandem, has raised $160M in total funding at a $1B valuation, backed by Thrive Capital, General Catalyst, and Accel. It was founded in 2023 by Sahir JaggiDealroom has a profile for this one. Try Dealroom →, who was named to the Forbes 30 Under 30 Healthcare list in 2025.
Forus builds AI software that automates the administrative process behind medical prescriptions. The moment a physician writes a prescription, Forus's system picks it up and handles the backend — checking what medications a patient has tried previously, identifying pharmacy restrictions, managing prior authorisation paperwork, and routing the prescription appropriately. Both doctor and patient can track the process in real time.
The software is free to providers and patients. Thousands of medical practices and health systems across the US use its platform, with a tenfold annual increase in adoption over the past two years driven almost entirely by word of mouth.
Why now? Around one third of Americans never fill the prescriptions their doctors order — a combination of cost, administrative friction, and pharmacy routing failures that costs both patients and the healthcare system enormously. Prior authorisation alone generates tens of millions of phone calls and fax exchanges between doctors' offices, insurers, and pharmacies every year. AI can automate most of that friction.
Forus's revenue is also accelerating sharply. Annualised revenue surpassed $10M by the end of 2025 and has roughly quintupled so far in 2026 — putting it on a trajectory above $50M. That pace of growth, achieved almost entirely through word of mouth, explains why three of the most respected US healthcare venture firms have backed it.
What could go wrong? Prescription management sits at the intersection of healthcare, insurance, and pharmacy — three of the most heavily regulated industries in the US. Any changes to prior authorisation rules, pharmacy benefit manager regulations, or insurance requirements could affect how Forus integrates with existing workflows. The company also faces competition from large incumbents like EpicDealroom has a profile for this one. Try Dealroom → and SurescriptsDealroom has a profile for this one. Try Dealroom → that have deep existing relationships with health systems.
Forus's revenue, while growing rapidly, is still modest relative to its $1B valuation — a multiple that demands sustained hypergrowth to justify.
The signal: Forus is a bet that healthcare's administrative burden — not its clinical complexity — is the most tractable problem for AI to solve first. The prescription fill rate failure is a well-documented, expensive, and largely unglamorous problem that has resisted improvement for decades because no single party had enough incentive or capability to fix it end-to-end. Forus is positioning itself as that neutral, AI-powered layer.
The backing of Thrive, General Catalyst, and Accel — three funds with strong healthcare track records — in successive rounds is a meaningful signal of conviction in both the team and the market timing.
Sources:
Forus
Business Wire
Forbes
Bloomberg
Image credit:
Forus
J.V.
